A Study of Foscarnet in the Treatment of HIV Infection in Patients Who Have Taken Zidovudine for a Long Time
Status:
Completed
Trial end date:
1991-06-01
Target enrollment:
Participant gender:
Summary
To study the toxicity, pharmacokinetics, and antiretroviral effectiveness of combined oral
zidovudine (AZT) and intermittent intravenous foscarnet therapy in stable AIDS or AIDS
related complex (ARC) patients who have already received AZT for 8 - 52 weeks.
It is hypothesized that the maximum AZT antiretroviral effect, which occurs at 8 weeks of
therapy, will be enhanced by 2 weeks of foscarnet treatment, given at the same time by
intermittent intravenous infusion. In addition, the further lowering of serum p24 antigen
concentration that should occur during combined therapy might continue when oral AZT therapy
is continued without foscarnet.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)